艾意凯咨询&研发客：2025创新前行全球共进：中国临床试验发展的新篇章研究报告（英文版）（49页）.pdf

1、 2025 L.E.K.Consulting1These materials are intended to supplement a discussion with L.E.K.Consulting.These perspectives will,therefore,only be meaningful to those in attendance.The contents of the materials are confidential and subject to obligations of non-disclosure.Your attention is drawn to the

2、full disclaimer contained in this document.Advancing Innovation and Global Reach:The Next Chapter in Chinas Clinical Trial Development PharmaDJ x L.E.K.Clinical Development ReportNovember 2025 2025 L.E.K.Consulting2Foreword:This report summarizes the key strategic trends of clinical development in C

3、hina,and can be referenced by pharmaceutical companies and CROs to support their R&D/service strategies Over the past decade,Chinas clinical development landscape has undergone a remarkable transformation.The market has expanded rapidly,fueled by favorable policy reforms and sustained R&D investment

4、 from pharmas.This evolution has laid a strong foundation for the next phase of growth,one characterized by deeper innovation,greater global integration of Chinese biopharmas/biotechs and the increasing adoption of smarter tools such as artificial intelligence(AI).As the industry continues to mature

5、,China is poised to emerge as a leading hub globally for innovation-driven clinical development.This report,produced in collaboration with PharmaDJ,provides a comprehensive overview of the strategic trends shaping Chinas clinical trial ecosystem today.It highlights not only the progress made in inno

6、vation,globalization and AI/smarter clinical trial tools,but also the opportunities facing both multinational and Chinese companies.Supported by a comprehensive survey of pharmaceutical companies and contract research organizations(CROs),this report serves as a starting point for multinational corpo